Back to Agenda
Session 2: Bioequivalence Considerations for Complex Generic Inhalation, Nasal, and Auto-Injector Drug-Device Combination Products (Continued)
Session Chair(s)
Kimberly A. Witzmann, MD
Acting Deputy Director, Office of Bioequivalence, Office of Generic Drugs, CDER, FDA, United States
Session 2: Bioequivalence Considerations for Complex Generic Inhalation, Nasal, and Auto-Injector Drug-Device Combination Products (Continued)
Speaker(s)
Roisin Wallace
Vice President, Head of Global Device Development and Operations, Viatris, Ireland
Moderator
Denise Conti, PhD, MSc
Senior Staff Fellow, Division of Therapeutic Performance, ORS, OGD, CDER, FDA, United States
Panelists
Anthony Hickey
Distinguished Fellow, RTI International, United States
Panelists
Guenther Hochhaus, PhD
Professor, University of Florida, United States
Panelists
Jason D. Rodriguez, PhD
Division Director, CDER/OPQ/OTR/Division of Complex Drug Analysis, FDA, United States
Panelists
Kimberly A. Witzmann, MD
Acting Deputy Director, Office of Bioequivalence, Office of Generic Drugs, CDER, FDA, United States
Panelists
Have an account?